Bringing a drug from discovery through clinical trials takes too long and is too expensive, with preclinical costs alone estimated at $15 to $100 million. Employing artificial intelligence (AI) early in the process can lower those costs dramatically. Jayson Uffens, CTO and chairman of GATC Health, emphasizes that while AI enhances the capabilities of researchers, human expertise remains invaluable in the drug development process.
GATC Health, an AI-driven therapeutic discovery company, leverages its proprietary AI platform, Operon, to accelerate the identification of high-potential compounds. This multi-omics approach enables the delivery of three to five optimized compounds within six months, significantly faster than traditional methods. By employing advanced in silico models, GATC aims to reduce the costly experiments typically needed to identify viable drug candidates.
The company’s innovative Derisq AI Report provides early insights into drug candidates, highlighting potential safety and efficacy issues, which is crucial for informed decision-making. This predictive intelligence forms the backbone of GATC’s clinical trial insurance product, which mitigates financial risks for biopharma companies, particularly those unable to self-insure. As GATC continues to refine its technology and partnerships, its focus on empowering researchers and expediting drug development could reshape the landscape of therapeutic discovery.
Start your 7-day trial and see what the database can do →
